We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 29, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amphastar Pharmaceuticals (AMPH - Free Report) , Abercrombie & Fitch (ANF - Free Report) , Cameco (CCJ - Free Report) , CyberArk Software (CYBR - Free Report) and LendingTree (TREE - Free Report) .
Here are highlights from Friday’s Analyst Blog:
5 Top Growth Stocks to Buy as Recession Fears Subside
The U.S. economy showed robustness in 2023 while expanding at a healthy pace in the final three months and squashing recession fearmongering. The domestic economy displayed astounding resilience in the face of the Federal Reserve's monetary tightening campaign to tame relentless price pressures. It continued to thrive, banking on the uptick in consumer outlays and strength in the labor market.
The U.S. economy accelerated at an annualized rate of 3.3% in the final quarter of 2023, more than economists' forecast of growth of 2%, according to the Commerce Department. In the third quarter, the economy grew at an annualized pace of 4.9%. Thus, the economy registered back-to-back strong readings despite higher interest rates and elevated inflation.
The U.S. economy, in reality, expanded by 2.5% for the whole of 2023, and became the fastest-growing advanced economy last year. This was also better than the 1.9% growth in 2022. The gross domestic product, nonetheless, improved in the fourth quarter due to steady consumer outlays, which rose 2.8%. Notably, consumer spending accounts for almost two-thirds of economic activity. Business investments and government outlays also increased in the reported quarter.
Most importantly, the personal consumption expenditures (PCE) price index that the Fed prefers as a long-term inflation measure, increased by 1.7% in the fourth quarter, less than the third quarter's reading of 2.6%, and very much around the central bank's 2% goal. What's more, in the fourth quarter, the core PCE advanced at an annual rate of 2%. Needless to say, the decline in prices of indispensable goods and services gave the wherewithal to consumers to spend and boost economic growth.
But it's not just in 2023, the economy is expected to trounce recession worries this year, too, and chug along. After all, economic activity is already off to a solid start, with the S&P flash U.S. services and manufacturing PMI climbing in January from the prior month.
Hence, with recession fears subsiding, and the economy continuing to bloom, the stock market is widely expected to experience a bull market, which calls for investing in growth stocks such as Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree (read more: 3 S&P 500 Growth Stocks to Buy as Index Enjoys Bull Market).
Amphastar Pharmaceuticals is a specialty pharmaceutical company. Amphastar Pharmaceuticals currently has a Zacks Rank #1 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 0.3% over the past 60 days. AMPH's expected earnings growth rate for the current year is 62.9%.
Abercrombie & Fitch operates as a specialty retailer of premium, high-quality casual apparel. Abercrombie & Fitch currently has a Zacks Rank #1 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 14.8% over the past 60 days. ANF's expected earnings growth rate for the current year is 2,320%.
Cameco is one of the world's largest uranium producers. Cameco currently has a Zacks Rank #1 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 12.5% over the past 60 days. CCJ's expected earnings growth rate for the current year is 188%.
CyberArk Software provides information technology security solutions. CyberArk Software currently has a Zacks Rank #2 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 2.6% over the past 60 days. CYBR's expected earnings growth rate for the current year is 277.3%.
LendingTree operates an online consumer platform in the United States. LendingTree currently has a Zacks Rank #1 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 0.5% over the past 60 days. TREE's expected earnings growth rate for the current year is 100%.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree
For Immediate Release
Chicago, IL – January 29, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amphastar Pharmaceuticals (AMPH - Free Report) , Abercrombie & Fitch (ANF - Free Report) , Cameco (CCJ - Free Report) , CyberArk Software (CYBR - Free Report) and LendingTree (TREE - Free Report) .
Here are highlights from Friday’s Analyst Blog:
5 Top Growth Stocks to Buy as Recession Fears Subside
The U.S. economy showed robustness in 2023 while expanding at a healthy pace in the final three months and squashing recession fearmongering. The domestic economy displayed astounding resilience in the face of the Federal Reserve's monetary tightening campaign to tame relentless price pressures. It continued to thrive, banking on the uptick in consumer outlays and strength in the labor market.
The U.S. economy accelerated at an annualized rate of 3.3% in the final quarter of 2023, more than economists' forecast of growth of 2%, according to the Commerce Department. In the third quarter, the economy grew at an annualized pace of 4.9%. Thus, the economy registered back-to-back strong readings despite higher interest rates and elevated inflation.
The U.S. economy, in reality, expanded by 2.5% for the whole of 2023, and became the fastest-growing advanced economy last year. This was also better than the 1.9% growth in 2022. The gross domestic product, nonetheless, improved in the fourth quarter due to steady consumer outlays, which rose 2.8%. Notably, consumer spending accounts for almost two-thirds of economic activity. Business investments and government outlays also increased in the reported quarter.
Most importantly, the personal consumption expenditures (PCE) price index that the Fed prefers as a long-term inflation measure, increased by 1.7% in the fourth quarter, less than the third quarter's reading of 2.6%, and very much around the central bank's 2% goal. What's more, in the fourth quarter, the core PCE advanced at an annual rate of 2%. Needless to say, the decline in prices of indispensable goods and services gave the wherewithal to consumers to spend and boost economic growth.
But it's not just in 2023, the economy is expected to trounce recession worries this year, too, and chug along. After all, economic activity is already off to a solid start, with the S&P flash U.S. services and manufacturing PMI climbing in January from the prior month.
Hence, with recession fears subsiding, and the economy continuing to bloom, the stock market is widely expected to experience a bull market, which calls for investing in growth stocks such as Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree (read more: 3 S&P 500 Growth Stocks to Buy as Index Enjoys Bull Market).
These stocks carry a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a Growth Score of A or B, a combination that offers the best opportunities in the growth investing space. You can see the complete list of today's Zacks Rank #1 stocks here.
Amphastar Pharmaceuticals is a specialty pharmaceutical company. Amphastar Pharmaceuticals currently has a Zacks Rank #1 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 0.3% over the past 60 days. AMPH's expected earnings growth rate for the current year is 62.9%.
Abercrombie & Fitch operates as a specialty retailer of premium, high-quality casual apparel. Abercrombie & Fitch currently has a Zacks Rank #1 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 14.8% over the past 60 days. ANF's expected earnings growth rate for the current year is 2,320%.
Cameco is one of the world's largest uranium producers. Cameco currently has a Zacks Rank #1 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 12.5% over the past 60 days. CCJ's expected earnings growth rate for the current year is 188%.
CyberArk Software provides information technology security solutions. CyberArk Software currently has a Zacks Rank #2 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 2.6% over the past 60 days. CYBR's expected earnings growth rate for the current year is 277.3%.
LendingTree operates an online consumer platform in the United States. LendingTree currently has a Zacks Rank #1 and a Growth Score of B. The Zacks Consensus Estimate for its current-year earnings has moved up 0.5% over the past 60 days. TREE's expected earnings growth rate for the current year is 100%.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.